An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, announced its participation in the William Blair & Company 42nd Annual Growth Stock Conference in Chicago on June 8, 2022, at 9:00 a.m. (Eastern Time). The presentation will be available for live audio webcast and a replay will follow. Insulet's Omnipod product platform aims to simplify diabetes management with innovative solutions, including the Omnipod 5 Automated Insulin Delivery System. This system is integrated with a continuous glucose monitor, providing a seamless insulin delivery experience.
Positive
None.
Negative
None.
ACTON, Mass.--(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair & Company 42nd Annual Growth Stock Conference in Chicago on Wednesday, June 8, 2022, at 9:00 a.m. (Eastern Time).
To listen to the live audio webcast of the presentation, please visit investors.insulet.com/events. A replay of the audio webcast will also be available following the event.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.
What event is Insulet Corporation participating in on June 8, 2022?
Insulet Corporation will present at the William Blair & Company 42nd Annual Growth Stock Conference in Chicago.
At what time will Insulet's presentation take place?
The presentation will take place at 9:00 a.m. (Eastern Time) on June 8, 2022.
How can I listen to the live audio webcast of the Insulet presentation?
You can listen to the live audio webcast at investors.insulet.com/events.
What is the focus of Insulet Corporation's Omnipod product platform?
The Omnipod product platform focuses on simplifying diabetes management through innovative tubeless insulin delivery systems.
What is the Omnipod 5 Automated Insulin Delivery System?
The Omnipod 5 is a tubeless automated insulin delivery system integrated with a continuous glucose monitor, allowing for seamless blood sugar management.
